A critical review of dupilumab for adult patients with prurigo nodularis.

Published in: Expert review of clinical immunology (2023)

Dupilumab is becoming the drug of choice for treatment of PN and may also be effective in treating patients with systemic underlying causes of their PN, although more studies are needed to assess this. Trials evaluating the long-term efficacy and durability of dupilumab in PN are also of interest.

Keyphrases

atopic dermatitis
drug induced
case control
adverse drug
decision making
electronic health record